Single-Domain Antibody-Based Protein Degrader for Synucleinopathies (Updated April 30, 2024).

A recent preprint abstract discusses the development of a potential therapeutic candidate for synucleinopathies, a group of neurodegenerative diseases characterized by the accumulation of a protein called alpha-synuclein in the brain. The researchers developed a single-domain antibody-based protein degrader that targets alpha-synuclein and a protein called Cereblon, which promotes its degradation. The study found that this therapeutic candidate enhanced the clearance of alpha-synuclein in cell cultures and mouse models of synucleinopathy. The researchers suggest that this approach shows promise for the treatment of synucleinopathies, although further research is needed. [Extracted from the article]